Octreotide Long-Acting Repeatable for the Treatment of Chronic Macular Edema in Uveiti

Purpoe To report on the efficacy of the omatotatin analog octreotide long-acting repeatable (LAR), in the treatment of uveitic chronic macular edema (CME). Deign Cae erie, retropective analyi. Method In 20 patient, 20 epiode of recurrent CME during otherwie quiecent uveiti were treated with intramucular octreotide LAR injection. Patient were included if CME control with acetazolamide or ytemic and periocular teroid had failed during previou CME epiode or if contraindication exited for peritent ue of thee therapie. Mean outcome point were CME and viual acuity change. Correlation of prognotic factor with thee outcome wa analyzed. Reult The included CME epiode occurred 7.6 ± 1.4 year after onet of uveiti. Octreotide LAR treatment tarted 7.0 ± 7.3 month after diagnoi of CME. CME decreaed in 70% of epiode, after 2.7 ± 1.3 month of treatment. After arret of ucceful treatment, CME recurred intantly (27.2%) or within ix month (36.4%). In 36.4% of uccefully treated epiode, CME wa abent for more than one year. A probable prognotic factor for ucce wa the duration of CME before treatment. Concluion Octreotide LAR had an edema-reducing effect in 70% of treated CME epiode. ucceful repone wa related to duration of CME before tart of treatment. The early recurrence of CME (63.6%) after arret of octreotide LAR advocate a long-term treatment in recent epiode of macular edema in otherwie quiecent uveiti.